Published in Biomed Res Int on March 22, 2016
The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.26
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol (2009) 14.42
Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol (2007) 10.75
Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol (2006) 9.99
CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA (2009) 7.29
APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol (2010) 6.17
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol (2013) 4.16
Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease. EMBO Mol Med (2009) 2.87
Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol (2011) 2.81
Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease. Ann Neurol (2010) 2.16
Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease. Neurology (2009) 1.99
The cerebrospinal fluid "Alzheimer profile": easily said, but what does it mean? Alzheimers Dement (2014) 1.88
Hypometabolism and altered cerebrospinal fluid markers in normal apolipoprotein E E4 carriers with subjective memory complaints. Biol Psychiatry (2007) 1.68
Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type. Arch Neurol (2009) 1.68
No association of CSF biomarkers with APOEepsilon4, plaque and tangle burden in definite Alzheimer's disease. Brain (2007) 1.63
Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment. Neurobiol Aging (2007) 1.61
Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. Neurology (2011) 1.56
Revised criteria for mild cognitive impairment: validation within a longitudinal population study. Dement Geriatr Cogn Disord (2006) 1.42
Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease. Alzheimers Dement (2014) 1.28
Epidemiological and economic burden of Alzheimer's disease: a systematic literature review of data across Europe and the United States of America. J Alzheimers Dis (2015) 1.03
Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease. JAMA Psychiatry (2014) 1.02
Integration and relative value of biomarkers for prediction of MCI to AD progression: spatial patterns of brain atrophy, cognitive scores, APOE genotype and CSF biomarkers. Neuroimage Clin (2013) 0.99
Relationship between CSF biomarkers of Alzheimer's disease and rates of regional cortical thinning in ADNI data. J Alzheimers Dis (2011) 0.99
Use of cerebrospinal fluid biomarkers for diagnosis of incipient Alzheimer disease in patients with mild cognitive impairment. Clin Chem (2009) 0.93
Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects. Brain (2015) 0.92
The effect of apolipoprotein E (ApoE) genotype on biomarkers of amyloidogenesis, tau pathology and neurodegeneration in Alzheimer's disease. Clin Chem Lab Med (2011) 0.92
CSF biomarkers in Alzheimer's disease and controls: associations with APOE genotype are modified by age. J Alzheimers Dis (2009) 0.92
Cerebrospinal fluid markers for Alzheimer's disease over the lifespan: effects of age and the APOEε4 genotype. J Alzheimers Dis (2010) 0.91
SUCLG2 identified as both a determinator of CSF Aβ1-42 levels and an attenuator of cognitive decline in Alzheimer's disease. Hum Mol Genet (2014) 0.90
Genetic interaction of PICALM and APOE is associated with brain atrophy and cognitive impairment in Alzheimer's disease. Alzheimers Dement (2014) 0.90
Quantitative assessment of apolipoprotein E genotypes by image analysis of PCR-RFLP fragments. Clin Chim Acta (2000) 0.86
Biochemical studies of poly-T variants in the Alzheimer's disease associated TOMM40 gene. J Alzheimers Dis (2012) 0.84
ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease. Neuroimage Clin (2014) 0.83
TOMM40 polymorphisms in Italian Alzheimer's disease and frontotemporal dementia patients. Neurol Sci (2013) 0.81
Alzheimer disease cerebrospinal fluid biomarkers predict cognitive decline in healthy elderly over 2 years. Alzheimer Dis Assoc Disord (2014) 0.79